Optimization of Immunosuppressive Therapy for Spinal Grafting of Human Spinal Stem Cells in a Rat Model of ALS

Previous rodent studies employing monotherapy or combined immunosuppressive regimens have demonstrated a variable degree of spinal xenograft survival in several spinal neurodegenerative models including spinal ischemia, trauma, or amyotrophic lateral sclerosis (ALS). Accordingly, the characterization of optimal immunosuppressive protocols for the specific neurodegenerative model is critical to ensure reliable assessment of potential long-term therapeutic effects associated with cell replacement. In the present study we characterized the survival of human spinal stem cells when grafted into the lumbar spinal cords of a rodent model of ALS, SOD1 (G93A) male and female rats (60–67 days old). Four different immunosuppressive protocols were studied: i) FK506 (q12h); ii) FK506 (qd) + mycophenolate (PO; q12h, up to 7 days postop); iii) FK506 (qd) + mycophenolate (IP; q12h, up to 7 days postop); and iv) FK506 (qd) + mycophenolate (IP; qd, up to 7 days postop). Three weeks after cell grafting the number of surviving human cells was then systematically assessed. The highest density of grafted cells was seen in animals treated with FK506 (qd) and mycophenolate (IP; qd; an average 915 ± 95 grafted cells per spinal cord section). The majority of hNUMA-positive cells colocalized with doublecortin (DCX) immunoreactivity. DCX-positive neurons showed extensive axodendritic sprouting toward surrounding host neurons. In addition, migrating grafted cells were identified up to 500 μm from the graft. In animals treated with FK506 (q12h), FK506 (qd) + mycophenolate (PO; q12h) or FK506 (qd) + mycophenolate (IP; q12h), 11.8 ± 3.4%, 61.2 ± 7.8%, and 99.4 ± 8.9% [expressed as percent of the FK506 (qd) and mycophenolate (IP; qd)] cell survival was seen, respectively. In contrast to animals treated with a combination of FK506 + mycophenolate, robust CD4/8 immunoreactivity was identified in the vicinity of the injection tract in animals treated with FK506 only. These data suggest that a combined, systemically delivered immunosuppression regimen including FK506 and mycophenolate can significantly improve survival of human spinal stem cells after intraspinal transplantation in SOD1 (G93A) rats.

[1]  E. Ingulli.  Mechanism of cellular rejection in transplantation , 2010, Pediatric Nephrology.

[2]  R. Deane,et al.  ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration , 2008, Nature Neuroscience.

[3]  Jonathan P. Riley,et al.  Shifting the balance: cell-based therapeutics as modifiers of the amyotrophic lateral sclerosis-specific neuronal microenvironment. , 2008, Neurosurgical focus.

[4]  P. Popovich,et al.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury , 2008, Experimental Neurology.

[5]  E. Haller,et al.  Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS , 2007, PloS one.

[6]  S. Kato.  Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[7]  C. Svendsen,et al.  GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS , 2007, PloS one.

[8]  S. Nicosia,et al.  Ultrastructure of blood–brain barrier and blood–spinal cord barrier in SOD1 mice modeling ALS , 2007, Brain Research.

[9]  M. Hefferan,et al.  Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells , 2007, Neuroscience.

[10]  Seung U. Kim,et al.  Stem Cell-Based Cell Therapy for Spinal Cord Injury , 2007, Cell transplantation.

[11]  V. Koliatsos,et al.  Extensive Neuronal Differentiation of Human Neural Stem Cell Grafts in Adult Rat Spinal Cord , 2007, PLoS medicine.

[12]  S. Lacroix,et al.  Proinflammatory cytokine synthesis in the injured mouse spinal cord: Multiphasic expression pattern and identification of the cell types involved , 2007, The Journal of comparative neurology.

[13]  C. Hulsebosch,et al.  Human fetal neural stem cells grafted into contusion‐injured rat spinal cords improve behavior , 2007, Journal of neuroscience research.

[14]  V. Koliatsos,et al.  Human Neural Stem Cell Grafts Ameliorate Motor Neuron Disease in SOD-1 Transgenic Rats , 2006, Transplantation.

[15]  V. Koliatsos,et al.  Combined Immunosuppressive Agents or CD4 Antibodies Prolong Survival of Human Neural Stem Cell Grafts and Improve Disease Outcomes in Amyotrophic Lateral Sclerosis Transgenic Mice , 2006, Stem cells.

[16]  H. Keirstead,et al.  Transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm. , 2006, Regenerative medicine.

[17]  J. Rothstein,et al.  Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS , 2006, Neurobiology of Disease.

[18]  P. Sanberg,et al.  Multiple transplants of hNT cells into the spinal cord of SOD1 mouse model of familial amyotrophic lateral sclerosis , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[19]  C. Svendsen,et al.  GDNF delivery using human neural progenitor cells in a rat model of ALS. , 2005, Human gene therapy.

[20]  Z. Tomori,et al.  Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study , 2004, Experimental Neurology.

[21]  Z. Tomori,et al.  Spinal implantation of hNT neurons and neuronal precursors: graft survival and functional effects in rats with ischemic spastic paraplegia , 2004, The European journal of neuroscience.

[22]  Jürgen Winkler,et al.  Transient expression of doublecortin during adult neurogenesis , 2003, The Journal of comparative neurology.

[23]  P. Mcgeer,et al.  Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[24]  R. Barker,et al.  Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS , 2002, The European journal of neuroscience.

[25]  P. Sanberg,et al.  Positive Effect of Transplantation of hNT Neurons (NTera 2/D1 Cell-Line) in a Model of Familial Amyotrophic Lateral Sclerosis , 2002, Experimental Neurology.

[26]  J. Glasby.  Shifting the balance. , 2001, Nursing older people.

[27]  K. Oyanagi,et al.  Adenoviral vector‐mediated GDNF gene transfer prevents death of adult facial motoneurons , 2000, Neuroreport.

[28]  G. Tydén,et al.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. , 1999, British journal of clinical pharmacology.

[29]  C. Walsh,et al.  Doublecortin Is a Microtubule-Associated Protein and Is Expressed Widely by Migrating Neurons , 1999, Neuron.

[30]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[31]  R. McKay,et al.  Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. , 1996, Genes & development.

[32]  J. Lipsky.  Mycophenolate mofetil , 1996, The Lancet.

[33]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[34]  J. Nikolić,et al.  Serum and CSF immunological findings in ALS , 1991, Acta neurologica Scandinavica.

[35]  J J Fung,et al.  Pharmacokinetics of FK 506: preclinical and clinical studies. , 1990, Transplantation proceedings.

[36]  L. Noble,et al.  Distribution and time course of protein extravasation in the rat spinal cord after contusive injury , 1989, Brain Research.

[37]  A. Schuyler,et al.  Strategic approaches to developing drug treatments for ALS. , 2008, Drug discovery today.

[38]  G. Abbruzzese,et al.  Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis , 2004, Journal of Neurology.